Generic Prezcobix Availability
Last updated on Aug 7, 2024.
Prezcobix is a brand name of cobicistat/darunavir, approved by the FDA in the following formulation(s):
PREZCOBIX (cobicistat; darunavir - tablet;oral)
-
Manufacturer: JANSSEN PRODS
Approval date: January 29, 2015
Strength(s): 150MG;800MG [RLD]
Has a generic version of Prezcobix been approved?
No. There is currently no therapeutically equivalent version of Prezcobix available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prezcobix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent 10,039,718
Issued: August 7, 2018
Inventor(s): Koziara Joanna M. & Menning Mark M. & Strickley Robert G. & Yu Richard & Kearney Brian P. & Mathias Anita A.
Assignee(s): Gilead Sciences, Inc.The invention provides a composition comprising, a compound of formula (I):
Patent expiration dates:
- October 6, 2032✓
- October 6, 2032
-
Patent 7,700,645
Patent expiration dates:
- December 26, 2026✓✓
- December 26, 2026
-
Patent 7700645*PED
Patent expiration dates:
- June 26, 2027✓
- June 26, 2027
-
Modulators of pharmacokinetic properties of therapeutics
Patent 8,148,374
Issued: April 3, 2012
Inventor(s): Desai Manoj C. & Liu Hongtao & Xu Lianhong
Assignee(s): Gilead Sciences, Inc.The present application provides for a compound of Formula IV,
Patent expiration dates:
- September 3, 2029✓✓✓
- September 3, 2029✓✓✓
- September 3, 2029
-
Pseudopolymorphic forms of a HIV protease inhibitor
Patent 8,518,987
Issued: August 27, 2013
Inventor(s): Vermeersch Hans Wim Pieter & Thone Daniel Joseph Christiaan & Janssens Luc Donne Marie-Louise & Wigerinck Piet Tom Bert Paul
Assignee(s): Janssen R&D IrelandNew pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Patent expiration dates:
- February 16, 2024✓✓
- February 16, 2024
-
Pseudopolymorphic forms of a HIV protease inhibitor
Patent 8518987*PED
Issued: August 27, 2013
Inventor(s): Vermeersch Hans Wim Pieter & Thone Daniel Joseph Christiaan & Janssens Luc Donne Marie-Louise & Wigerinck Piet Tom Bert Paul
Assignee(s): Janssen R&D IrelandNew pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Patent expiration dates:
- August 16, 2024✓
- August 16, 2024
More about Prezcobix (cobicistat / darunavir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
